Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1431211
This article is part of the Research Topic Regulators of the Immune-Tumor Microenvironment: A New Frontier for Cancer Immunotherapy View all 10 articles

Regulatory T Cells and Immune Escape in HCC: Understanding the Tumor Microenvironment and Advancing CAR-T Cell Therapy

Provisionally accepted
Guangtan Du Guangtan Du 1Cunmiao Dou Cunmiao Dou 1PENG SUN PENG SUN 2Shasha Wang Shasha Wang 1*Jia Liu Jia Liu 3*Leina Ma Leina Ma 1*
  • 1 Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China
  • 2 Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China
  • 3 Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong Province, China

The final, formatted version of the article will be published soon.

    Liver cancer, which most commonly manifests as hepatocellular carcinoma (HCC), is the sixth most common cancer in the world. In HCC, the immune system plays a crucial role in the growth and proliferation of tumor cells. HCC achieve immune escape through the tumor microenvironment, which significantly promotes the development of this cancer.Here, this article introduces and summarizes the functions and effects of regulatory T cells (Tregs) in the tumor microenvironment, highlighting how Tregs inhibit and regulate the functions of immune and tumor cells, cytokines, ligands and receptors, etc, thereby promoting tumor immune escape. In addition, it discusses the mechanism of CAR-T therapy for HCC and elaborate on the relationship between CAR-T and Tregs.

    Keywords: hepatocellular carcinoma1 (HCC), tumor microenvironment2, CAR-T5, regulatory T cells3(Treg), immunotherapy4

    Received: 11 May 2024; Accepted: 12 Jul 2024.

    Copyright: © 2024 Du, Dou, SUN, Wang, Liu and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Shasha Wang, Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong Province, China
    Jia Liu, Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, 266021, Shandong Province, China
    Leina Ma, Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.